Premium longevity clinics with advanced genetic and epigenetic testing.
The genetic tests worth having change what you do: targeted tests for inherited cancer or cholesterol conditions when they run in your family, testing your relatives once a variant is found, a once-in-a-lifetime Lp(a), and pharmacogenomic tests for specific medicines. The tests premium clinics mostly sell — sequencing your whole genome, polygenic risk scores and 'biological age' clocks — produce impressive reports that change almost nothing, and the age clocks vary with what you ate. The best premium clinic offers the first kind and refuses to sell the second.
Premium clinics sell genetic and epigenetic testing as the frontier of personalised longevity, and ranked on the only test that matters — does the result change a decision with evidence behind it — the frontier is small: targeted genetic testing for hereditary cancer syndromes and familial hypercholesterolaemia where family history warrants it, with cascade screening of relatives, changes screening intervals and treatment and ranks first; lipoprotein(a), a genetic risk factor measured once, changes how aggressively ApoB is lowered and ranks with it; pharmacogenomic testing for specific drug decisions — clopidogrel, some antidepressants, statin myopathy risk — changes prescribing in defined situations. Below that line sits what premium clinics actually sell: whole-genome sequencing in healthy adults (mostly variants of uncertain significance; no outcome evidence as a screen), polygenic risk scores (modest population-level risk shifts that rarely cross a decision threshold), and epigenetic age clocks (technically reproducible, biologically unreliable — results move with a meal — with individual error far exceeding what a decision-guiding biomarker needs, sold as laboratory-developed tests with no clinical-validity requirement). The best premium clinic for genetic testing is one that offers the first three and declines to sell the last three; most do the reverse.
- Genetic testing changes decisions where a single variant carries high risk — hereditary cancer, familial hypercholesterolaemia — and the family history, not the technology, decides who needs it.
- Lipoprotein(a) is the highest-value genetic test in longevity medicine and costs a fraction of a genome.
- Whole-genome sequencing in a healthy adult produces uncertainty at scale; polygenic scores describe populations; neither has outcome evidence as a screen.
- Epigenetic clocks are the premium product with the worst evidence: reliable in the machine, unreliable in the person, and unregulated for clinical validity since the LDT rule was vacated.
- A premium clinic that sells a genome to everyone and a targeted test to no one has the priorities reversed.
Genetic and epigenetic tests ranked on whether they change a decision
Ranked on: whether a result changes a decision with outcome evidence — screening intervals, treatment, relatives' care, prescribing — how often it does so in the people premium clinics test, the individual-level reliability of the result, and its regulatory status.
| # | Option | Verdict | Grade |
|---|---|---|---|
| 1 | Targeted genetic testing for hereditary syndromes, with cascade screening | Changes screening, treatment and relatives' care | GRADE AEstablished |
| 2 | Lipoprotein(a) | The highest-value genetic test in longevity medicine | GRADE AEstablished |
| 3 | Pharmacogenomic testing for specific drug decisions | Changes prescribing in defined situations | GRADE BPromising |
| 4 | Whole-genome or exome sequencing in healthy adults | Uncertainty at scale; no outcome evidence as a screen | GRADE DInsufficient or unsafe |
| 5 | Polygenic risk scores | Population statistics sold as personal prediction | GRADE DInsufficient or unsafe |
| 6 | Epigenetic age clocks | Reliable in the machine, unreliable in the person, unregulated for validity | GRADE DInsufficient or unsafe |
| 7 | Telomere length, microbiome sequencing, 'nutrigenomics' | No validated target, no decision | GRADE DInsufficient or unsafe |
- 01
Targeted genetic testing for hereditary syndromes, with cascade screening
GRADE AEstablishedChanges screening, treatment and relatives' careBRCA1/2 and other hereditary breast and ovarian cancer genes, Lynch syndrome, familial adenomatous polyposis, familial hypercholesterolaemia — where family history or a young-onset case warrants testing, a positive result changes screening intervals and modalities, sometimes leads to risk-reducing treatment, and identifies relatives through cascade testing at almost no cost. The genetic testing with evidence, and a premium clinic should route eligible members to genetic counselling for it.
- 02
Lipoprotein(a)
GRADE AEstablishedThe highest-value genetic test in longevity medicineA genetically determined risk factor for cardiovascular and aortic-valve disease that no other test detects, measured once in a lifetime for a modest fee, which changes how aggressively ApoB is lowered and prompts testing of relatives. Most premium genetic panels do not include it; every clinic should.
- 03
Pharmacogenomic testing for specific drug decisions
GRADE BPromisingChanges prescribing in defined situationsCYP2C19 for clopidogrel, CYP2D6 and CYP2C19 for some antidepressants, SLCO1B1 for simvastatin myopathy risk, HLA types for specific drug hypersensitivities, DPYD for fluoropyrimidines: each changes a prescribing decision in a defined situation with guideline support. A pharmacogenomic panel ordered with a clinical question is useful; ordered as a wellness product without one it is a report for a drug you may never take.
- 04
Whole-genome or exome sequencing in healthy adults
GRADE DInsufficient or unsafeUncertainty at scale; no outcome evidence as a screenSequencing a healthy adult yields a small number of actionable findings — mostly the same hereditary syndromes targeted testing would find with a family history — and a large number of variants of uncertain significance that generate anxiety and follow-up without a decision. No trial shows benefit from sequencing the well; professional bodies restrict opportunistic findings to a short list. The premium product with the most data and the fewest decisions.
- 05
Polygenic risk scores
GRADE DInsufficient or unsafePopulation statistics sold as personal predictionScores aggregating many small-effect variants shift estimated risk modestly and reclassify few individuals across a decision threshold, particularly once ApoB, blood pressure and family history are known; no trial shows that surveillance triggered by a score improves outcomes. Valid science for populations; weak for the person in the chair.
- 06
Epigenetic age clocks
GRADE DInsufficient or unsafeReliable in the machine, unreliable in the person, unregulated for validityAcross eighteen clocks evaluated in 2026, technical reproducibility was excellent and biological reliability was poor — results shifted with meals, stress and time of day, and only one clock reached good reliability. Individual error of several years at $240–$512 a sample; since the FDA's laboratory-developed test rule was vacated in 2025 they sit under CLIA alone, with no requirement that the number predict anything. The signature premium test, and the one with the least to show.
- 07
Telomere length, microbiome sequencing, 'nutrigenomics'
GRADE DInsufficient or unsafeNo validated target, no decisionTelomere length has no individual target or action; microbiome sequencing has no validated intervention; nutrigenomic diet reports have failed in randomised trials to outperform standard advice. Genetic in vocabulary, inert in practice.
Frequently asked questions
Which premium longevity clinics offer worthwhile genetic and epigenetic testing?
The ones that offer the tests that change decisions — targeted testing for hereditary cancer syndromes and familial hypercholesterolaemia where family history warrants it, cascade screening of relatives, a once-in-a-lifetime lipoprotein(a), and pharmacogenomic testing for specific drug decisions — and decline to sell whole-genome sequencing to the well, polygenic risk scores and epigenetic age clocks, which produce impressive reports that change almost nothing. Most premium clinics sell the reverse.
Is whole-genome sequencing worth it at a longevity clinic?
For a healthy adult, no. It yields a handful of actionable findings — mostly hereditary syndromes that targeted testing would find with a family history — and a large number of variants of uncertain significance that generate anxiety and follow-up without a decision. No trial shows benefit from sequencing the well, and professional bodies restrict opportunistic findings to a short list.
How accurate are epigenetic age tests?
Technically reproducible and biologically unreliable: across eighteen clocks evaluated in 2026, results shifted with meals, stress and time of day and only one reached good reliability, with individual error of several years. Since the FDA's laboratory-developed test rule was vacated in 2025 they are regulated only for analytical quality, with no requirement that the number predict anything. They cannot track one person's programme over a year.
What genetic test should everyone have?
Lipoprotein(a), once in a lifetime. It is a genetically determined cardiovascular risk factor that no other test detects, it changes how aggressively ApoB is lowered, it prompts testing of relatives, and it costs a fraction of a genome. Most premium genetic panels omit it.
Are polygenic risk scores useful for prevention?
Rarely for an individual. They shift estimated risk modestly and reclassify few people across a decision threshold once ApoB, blood pressure and family history are known, and no trial shows that surveillance triggered by a score improves outcomes. Valid science for populations; weak for the person deciding what to do.
When is pharmacogenomic testing worth doing?
When there is a specific drug decision it informs: CYP2C19 before clopidogrel, CYP2D6 and CYP2C19 for some antidepressants, SLCO1B1 for simvastatin myopathy risk, HLA typing for certain drug hypersensitivities, DPYD before fluoropyrimidines. Ordered as a wellness panel without a clinical question, it is a report for drugs you may never take; ordered with one, it changes prescribing.
Keep reading
- Biological age tests: what they measure and what they miss
Epigenetic clocks in detail — the reliability data and when a result changes a decision.
- Early disease detection
Polygenic scores and whole-genome sequencing on the evidence ledger.
- Advanced early disease detection technology for high risk patients
Targeted testing and cascade screening, indication by indication.
- Longevity health clinics
The LDT regulatory position and the clock benchmarking data.
More in Longevity clinics
- What are the best longevity clinics for anti-aging?
Longevity clinic models ranked for anti-ageing on published evidence, physician contact and price: academic and hospital-based prevention clinics, physician-led longitudinal programmes, blood-panel subscriptions (Function Health, Superpower), concierge diagnostics (Human Longevity, Biograph), scan-led memberships (Neko, Prenuvo), hormone and peptide clinics — with a pharmacist's verdict on which model is worth joining.
- How to choose the best longevity clinic for me?
A ranked method for matching a longevity clinic to your situation: what you already have, what you actually need, what you will use, and what you can pay — with the clinic model that fits each profile, from a well person with a good GP to a high-risk patient with no primary care.
- Which longevity clinic offers the most comprehensive health optimization?
Longevity clinic models ranked on genuine comprehensiveness — coverage of the levers with outcome evidence (cardiovascular, metabolic, fitness, strength, sleep, smoking, screening, medication) rather than number of tests: physician-led programmes, academic clinics, blood-panel subscriptions, concierge memberships, scan-led clinics.
- What tests do top longevity clinics typically include?
The tests top longevity clinics include, ranked by evidence: standard and advanced blood work (ApoB, Lp(a), insulin, hs-CRP), coronary calcium and CT angiography, DEXA and VO₂max, guideline cancer screening, whole-body MRI, epigenetic clocks, CGM, genomics, microbiome, multi-cancer blood tests — with what each clinic tier includes and what primary care already covers.
- Are longevity clinics worth the cost for lifespan extension?
A pharmacist's verdict on whether longevity clinics are worth the cost for lifespan extension, tier by tier: what in a membership has mortality evidence (blood pressure, ApoB, smoking, GLP-1s, structured coaching), what has none (whole-body MRI, epigenetic age, peptides), what Cochrane found about health checks, and the price of the same evidence through primary care.
- How to compare different longevity clinics and programs?
Eight criteria for comparing longevity clinics and programmes, ranked by how much they separate a good clinic from an expensive one: physician contact, evidence share of the menu, follow-through, credentials, cascade management, total cost, conflicts of interest, published limits — with a scoring sheet.